Exelixis Announces Third Quarter 2023 Financial Results and

- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million -


- Conference Call and Webcast Today at 5:00 PM Eastern Time -

...

Related Keywords

Delaware , United States , New York , Michaelm Morrissey , Amy Peterson , Thomas Jefferson University , National Cancer Institute , Product Development Medical Affairs , International Kidney Cancer Symposium , Genentech , Teva Pharmaceuticals United States Inc , University Of Chicago , Us District Court , Exelixis Inc , Facebook , Takeda Pharmaceutical Company , Exchange Commission , Share Repurchase Program , Teva Pharmaceuticals , European Society For Medical Oncology , Nasdaq , Alliance For Clinical Trials In Oncology , Drug Administration , Teva Pharmaceuticals Development Inc , Chief Executive Officer , Chief Medical Officer , Kidney Cancer Symposium , Insilico Medicine , Ipsen Pharma , Accepted Accounting Principles , Franchise Net Product Revenues , Trial Evaluating Cabozantinib , Metastatic Castration Resistant Prostate Cancer , Advanced Pancreatic , Extra Pancreatic Neuroendocrine Tumors Presented , Medical Oncology , Clinical Trials , Safety Monitoring Board , Interim Analysis , License Agreement , Teva Pharmaceuticals Development , Teva Pharmaceuticals United States , Abbreviated New Drug Application , Executive Vice President , Product Development , Medical Affairs , Chief Medical , Northwestern Memorial Hospital , Exclusive Global License Agreement , Potentially Best In Class , Event Calendar , Annual Report , Quarterly Reports , Months Ended September , Accounting Standards Codification Topic , Markets ,